Analyst Price Targets — OCS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 4, 2026 9:46 pm | Annabel Samimy | Stifel Nicolaus | $50.00 | $27.72 | StreetInsider | Oculis Holding AG (OCS) PT Raised to $50 at Stifel |
| December 19, 2025 12:42 pm | Annabel Samimy | Stifel Nicolaus | $40.00 | $20.98 | StreetInsider | Oculis Holding AG (OCS) PT Raised to $40 at Stifel; An 'Under-the-Radar Name' |
| October 8, 2025 11:08 am | — | Chardan Capital | $51.00 | $19.06 | TheFly | Oculis price target raised to $51 from $33 at Chardan |
| October 7, 2025 10:13 am | Yi Chen | H.C. Wainwright | $36.00 | $18.56 | TheFly | Oculis price target raised to $36 from $33 at H.C. Wainwright |
| August 22, 2025 10:05 am | — | H.C. Wainwright | $33.00 | $17.85 | TheFly | Oculis price target raised to $33 from $32 at H.C. Wainwright |
| June 11, 2024 6:08 am | Yi Chen | H.C. Wainwright | $30.00 | $12.00 | TheFly | Oculis price target raised to $30 from $28 at H.C. Wainwright |
| June 10, 2024 4:20 pm | Colleen Kusy | Robert W. Baird | $37.00 | $12.00 | TheFly | Oculis price target raised to $37 from $35 at Baird |
Latest News for OCS
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced completion of the final patient visit in the OCS-01 Phase 3 DIAMOND program in diabetic macular edema (DME). Oculis expects to report…
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced completion of the final patient visit in the OCS-01 Phase 3 DIAMOND program in diabetic macular edema (DME). Oculis expects to report…
ZUG, Switzerland, April 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.
ZUG, Switzerland, April 07, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, announced today that Oculis' management will participate in upcoming investor conferences in April.
ZUG, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that its neuroprotective candidate Privosegtor has been granted Priority Medicines (PRIME) designation by the European Medicines Agency…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for OCS.
Senate Trading
No Senate trades found for OCS.
U.S. House Trading
No House trades found for OCS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.